The effect of ruboxistaurin on nephropathy in type 2 diabetes.
about
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System BlockadePresent and future in the treatment of diabetic kidney diseaseMolecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targetsDiabetic kidney disease: from physiology to therapeuticsRegenerative therapies for diabetic microangiopathyDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsEvolving pandemic diabetic nephropathyTherapeutic Modalities in Diabetic Nephropathy: Future Approaches.Diabetic neuropathy: mechanisms to managementActivation of protein kinase C isoforms and its impact on diabetic complications.Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetesDiabetic nephropathy - complications and treatment.Association between diabetes mellitus with metabolic syndrome and diabetic microangiopathy.Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitusExercise protects against diet-induced insulin resistance through downregulation of protein kinase Cβ in miceSulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.Effects of Minocycline on Urine Albumin, Interleukin-6, and Osteoprotegerin in Patients with Diabetic Nephropathy: A Randomized Controlled Pilot Trial.Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?Comprehensive approach to diabetic nephropathy.Vascular complications of diabetes: mechanisms of injury and protective factorsClinical safety of the selective PKC-beta inhibitor, ruboxistaurin.Implications of treatment that target protective mechanisms against diabetic nephropathyProtein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy.Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment.Treating insulin resistance: future prospects.Prostaglandin I2 Receptor Agonism for Proteinuria and Diabetes: Good for the Goose and Good for the Gander?Diabetes and the endothelium.Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: re-visiting glycated haemoglobin targets for cardiovascular disease prevention.Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.Protein kinase C, an elusive therapeutic target?Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.Local cAMP signaling in disease at a glanceNew insights into molecular mechanisms of diabetic kidney disease.Ruboxistaurin: PKC-beta inhibition for complications of diabetes.The renal effects of blood glucose-lowering plant-derived extracts in diabetes mellitus--an overview.Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice.New approaches to the treatment of nephropathy in diabetes.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.
P2860
Q26799443-B6BF7E50-841D-4B6E-8A66-293DEA2AEDF7Q26864133-B4B277B2-7AEF-46BC-BCCE-4D433221085BQ27014620-A2886479-106C-4C9D-92CE-FFE32E785A4EQ27021392-67191528-DA5E-4E9D-8AF6-68BEB318102DQ27027852-E31FE18D-A3FE-497D-B393-459465D1B0B2Q28086840-88960700-42A9-47B6-BB6C-CC3EB9A7C180Q30352538-4E8F0563-9D98-4C7D-9696-162345CDA68DQ30423005-BB4111F0-217C-436F-A1E8-385A23769AC6Q33554384-DF218B17-6936-4FE0-AFEB-004961E55AD0Q33881442-B4DC3B6B-4376-4681-8B29-E9D898737B0AQ34031989-D0876C33-A395-4B65-8A44-32DBFC0C7F8AQ34387952-718143C3-B180-4EEA-AC86-7757A4291B4FQ34443979-5AEAA6A0-ED53-4EB5-8E65-1712A4612364Q34931190-40C764F7-B612-4297-B43F-BF8B445B10ECQ35069551-14F35781-8FB6-4509-89F3-ECBA21ACB3D3Q35720773-8644D0DD-A4C5-47F0-A0E8-B4F85954A07EQ35953867-BDD6D287-559F-42E6-9E5A-05F114A50FE9Q35971663-316F0CD9-5E57-4B47-9A5F-93079D1AA62FQ36293649-D00EA1BE-8152-4304-BF05-415FE7880969Q36466019-B0F2B020-320F-456C-9765-38AA23355A3AQ36537262-654B7DE9-F353-42B6-A81C-1E2AA42805A0Q36624994-F11AA7D9-ECAD-4AF4-9E0B-8F49366445EEQ36645971-513BA174-9D49-4E09-9039-183F821105E9Q36679604-3C0B19C2-2387-47A4-B66A-C7E1744F9587Q36785571-678A7106-19CF-4F43-83A8-562AACB6CE47Q36806514-FD203C35-D057-41F0-8B91-45D05EA8B613Q36820725-7C09A438-BEE8-4A45-9ED0-5E06761F39BFQ36839528-511E7053-ACCB-40D5-A270-C94B64BA9650Q36966069-E3279B2F-9F2B-49C2-94B3-AD54CE39EE5AQ37058905-67AD46CC-5843-4EFC-A6BC-A673D1AEF77EQ37072778-B2E3E590-B3C4-44EA-B8A0-3FD478376DFEQ37141320-9BF42956-87CD-41B4-A46B-3540150099F4Q37165694-F6583979-FD1E-492E-A42E-6D847DE9F63EQ37226387-4656EDB4-A350-4AF3-9D83-48C8E1DE3B3EQ37598306-399A1651-F3D1-4925-87FF-299E65C0C96AQ37636163-2C030997-7FF1-4700-9225-491D0C80C1A5Q37683784-9AD65FDB-C126-46C0-91B8-2663492D0907Q37741992-DFBE95FE-3660-4AFE-A6C5-A063501DD566Q37899907-B2A1F327-3158-4B32-A63B-326E72A1DE44Q37904098-B284B374-9582-4A42-B066-13733D9C7916
P2860
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
@en
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
@nl
type
label
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
@en
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
@nl
prefLabel
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
@en
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
@nl
P2093
P1433
P1476
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
@en
P2093
George L Bakris
Janet B McGill
Katherine R Tuttle
Kuolung Hu
Pamela W Anderson
Robert D Toto
P304
P356
10.2337/DIACARE.28.11.2686
P407
P577
2005-11-01T00:00:00Z